U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
One Percent Rule Checklist For Safer Forex Trading Risk 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
TEL AVIV, Israel, April 06, 2017 -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today the cancellation of its previously announced underwritten public offering of the company’s securities due to adverse market conditions. The offering was conducted pursuant to a registration statement Form F-1 filed with the U.S. Securities and Exchange Commission.
The Company will provide a business update in the near future that deals with its financing plans and clinical development program for patients with Ocular Pharyngeal Muscular Dystrophy (OPMD) using its investigational proprietary intravenous (IV) form of trehalose 90 mg/mL solution.
About Bioblast Pharma Ltd.
Bioblast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Bioblast is traded on the NASDAQ under the symbol “ORPN”. For more information, please visit our website: www.BioblastPharma.com, the content of which is not incorporated herein by reference.
INVESTOR CONTACT Matthew P. Duffy Managing Director LifeSci Advisors LLC [email protected] Phone: 212-915-0685
